Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| FDA Approves Merck's JUVISYNC(TM) (sitagliptin and simvastatin) Tablets, a ... - MarketWatch (press release) |
 |
 |
|
MarketWatch (press release) Because doses of JUVISYNC appropriate for patients with moderate or severe renal impairment (CrCl <50 mL/min, approximately corresponding to serum creatinine levels of >1.7 mg/dL in men and >1.5 mg/dL in women) or end-stage renal disease (ESRD) are not |
